In this episode, we spotlight Forum Discussion 03 from the AD/PD™ 2025 International Conference: “Improving the Therapeutic Potential of Immunotherapies in AD – Can Novel Strategies or Next Generation Drugs Halt or Further Delay Disease Progression?”
Chaired by Dr. Rudolph Tanzi (USA) and Dr. Suzanne Hendrix (USA), this thought-provoking panel brought together leaders in Alzheimer’s disease research and development: Dr. Chad Swanson, Dr. Donna Wilcock, Dr. Yuval Zabar, Dr. Janice Smith, and Dr. Eric Siemers.
The discussion centered on how the next generation of Alzheimer’s immunotherapies can go beyond current anti-amyloid treatments. With an eye on efficacy, safety, accessibility, and clinical outcomes, the panel explored what’s needed to truly move the field forward.
Key highlights include:
• The limitations of current anti-amyloid therapies and how to maximize their real-world impact• Infrastructure and access issues — from infusion centers to specialist shortages
• Potential of next-gen strategies, including combination therapies and novel mechanisms
• The role of blood-based biomarkers and real-world data in refining treatment selection
• Challenges and promise of active vaccination for long-term AD prevention
• Cost-effectiveness and the need to measure outcomes that truly matter to patients
This episode is relevant for clinical researchers, neurologists, biotech developers, regulatory experts, and anyone invested in the future of disease-modifying treatments for Alzheimer’s.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/